STAT

Mental health apps are scooping up your most sensitive data. Will you benefit?

Mental health apps can put patients’ privacy at risk, and makers of some tools are using the data collected to create products that have nothing to do with health care.

An app for monitoring people with bipolar disorder and schizophrenia is so precise it can track when a patient steps outside for a cigarette break or starts a romantic relationship — and where that new partner lives. Another app, meant to screen for suicidality, analyzes not only text message metadata, but also the content of the conversations.

While these smartphone trackers are being developed through academic research projects, which require patients to give informed consent before sharing intensely personal information, mental health apps without such safeguards are already on the market for depression, anxiety, PTSD, and other conditions.

Many of these apps have a common problem, say experts on health technology: They put patients’ privacy at risk while providing marginal or unknown benefits. And in some cases, without customers’ knowledge, makers of mental health apps or services are using the data collected to create products that have nothing to do with health care.

Phone apps hold enormous promise for mental health research and treatment, and could even prevent acute episodes of psychosis or suicide attempts. They’re always with the patient, unobtrusively monitoring sleep patterns, movements, location, and social interactions, providing clinicians insight into a person’s life that a monthly appointment

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks